Health
Researchers receive $5.1 million to expand clinical trial of drug to prevent ARDS in COVID-19 patients – News-Medical.Net
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress s to expand the Phase II clinical trial at…
Researchers evaluating whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients were awarded $5.1 million in funding from the U.S. Department of Defense (DOD) to expand the Phase II clinical trial at The University of Texas Health Science Center at HoustonQ (UTHealth).
Vadadustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, or HIF-PHI, designed to mimic the physiologic effect of altitude…
-
Noosa News23 hours agoQueensland government to introduced artificial intelligence teaching tool Corella to all state high schools
-
Business14 hours agoThe pros and cons of buying CBA shares in September
-
Noosa News21 hours agoMan charged with murder three days after death of 27-year-old in Livingstone, QLD
-
Noosa News14 hours agoRent changes on way for hundreds of social housing recipients following government review